OBJECTIVE: To elucidate the pathophysiologic links between prostaglandin E(2) (PGE(2)) and osteoarthritis (OA) by characterizing the catabolic effects of PGE(2) and its unique receptors in human adult articular chondrocytes. METHODS: Human adult articular chondrocytes were cultured in monolayer or alginate beads with and without PGE(2) and/or agonists of EP receptors, antagonists of EP receptors, and cytokines. Cell survival, proliferation, and total proteoglycan synthesis and accumulation were measured in alginate beads. Chondrocyte-related gene expression and phosphatidylinositol 3-kinase/Akt signaling were assessed by real-time reverse transcription-polymerase chain reaction and Western blotting, respectively, using a monolayer cell culture model. RESULTS: Stimulation of human articular chondrocytes with PGE(2) through the EP2 receptor suppressed proteoglycan accumulation and synthesis, suppressed aggrecan gene expression, did not appreciably affect expression of matrix-degrading enzymes, and decreased the type II collagen:type I collagen ratio. EP2 and EP4 receptors were expressed at higher levels in knee cartilage than in ankle cartilage and in a grade-dependent manner. PGE(2) titration combined with interleukin-1 (IL-1) synergistically accelerated expression of pain-associated molecules such as inducible nitric oxide synthase and IL-6. Finally, stimulation with exogenous PGE(2) or an EP2 receptor-specific agonist inhibited activation of Akt that was induced by insulin-like growth factor 1. CONCLUSION: PGE(2) exerts an antianabolic effect on human adult articular cartilage in vitro, and EP2 and EP4 receptor antagonists may represent effective therapeutic agents for the treatment of OA.
OBJECTIVE: To elucidate the pathophysiologic links between prostaglandin E(2) (PGE(2)) and osteoarthritis (OA) by characterizing the catabolic effects of PGE(2) and its unique receptors in human adult articular chondrocytes. METHODS:Human adult articular chondrocytes were cultured in monolayer or alginate beads with and without PGE(2) and/or agonists of EP receptors, antagonists of EP receptors, and cytokines. Cell survival, proliferation, and total proteoglycan synthesis and accumulation were measured in alginate beads. Chondrocyte-related gene expression and phosphatidylinositol 3-kinase/Akt signaling were assessed by real-time reverse transcription-polymerase chain reaction and Western blotting, respectively, using a monolayer cell culture model. RESULTS: Stimulation of human articular chondrocytes with PGE(2) through the EP2 receptor suppressed proteoglycan accumulation and synthesis, suppressed aggrecan gene expression, did not appreciably affect expression of matrix-degrading enzymes, and decreased the type II collagen:type I collagen ratio. EP2 and EP4 receptors were expressed at higher levels in knee cartilage than in ankle cartilage and in a grade-dependent manner. PGE(2) titration combined with interleukin-1 (IL-1) synergistically accelerated expression of pain-associated molecules such as inducible nitric oxide synthase and IL-6. Finally, stimulation with exogenous PGE(2) or an EP2 receptor-specific agonist inhibited activation of Akt that was induced by insulin-like growth factor 1. CONCLUSION:PGE(2) exerts an antianabolic effect on human adult articular cartilage in vitro, and EP2 and EP4 receptor antagonists may represent effective therapeutic agents for the treatment of OA.
Authors: M Mathy-Hartert; S Burton; G Deby-Dupont; P Devel; J-Y Reginster; Y Henrotin Journal: Osteoarthritis Cartilage Date: 2005-01 Impact factor: 6.576
Authors: Christine A Clark; Edward M Schwarz; Xinping Zhang; Navid M Ziran; Hicham Drissi; Regis J O'Keefe; Michael J Zuscik Journal: Biochem Biophys Res Commun Date: 2005-03-18 Impact factor: 3.575
Authors: A R Amin; M Attur; R N Patel; G D Thakker; P J Marshall; J Rediske; S A Stuchin; I R Patel; S B Abramson Journal: J Clin Invest Date: 1997-03-15 Impact factor: 14.808
Authors: K Nakata; K Ono; J Miyazaki; B R Olsen; Y Muragaki; E Adachi; K Yamamura; T Kimura Journal: Proc Natl Acad Sci U S A Date: 1993-04-01 Impact factor: 11.205
Authors: K V Greco; A J Iqbal; L Rattazzi; G Nalesso; N Moradi-Bidhendi; A R Moore; M B Goldring; F Dell'Accio; M Perretti Journal: Biochem Pharmacol Date: 2011-09-16 Impact factor: 5.858
Authors: Deirtra A Hunter; Gordon A Barr; Kai-Yvonne Shivers; Nicole Amador; Shirzad Jenab; Charles Inturrisi; Vanya Quinones-Jenab Journal: Brain Res Date: 2011-01-31 Impact factor: 3.252
Authors: Andrew S Lee; Michael B Ellman; Dongyao Yan; Jeffrey S Kroin; Brian J Cole; Andre J van Wijnen; Hee-Jeong Im Journal: Gene Date: 2013-07-02 Impact factor: 3.688